COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F22%3A00076116" target="_blank" >RIV/65269705:_____/22:00076116 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/22:00128743
Result on the web
<a href="https://ashpublications.org/bloodadvances/article/6/7/2427/477883/COVID-19-and-CAR-T-cells-a-report-on-current" target="_blank" >https://ashpublications.org/bloodadvances/article/6/7/2427/477883/COVID-19-and-CAR-T-cells-a-report-on-current</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/bloodadvances.2021005616" target="_blank" >10.1182/bloodadvances.2021005616</a>
Alternative languages
Result language
angličtina
Original language name
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
Original language description
Since it was first reported in China, coronavirus disease 2019 (COVID-19) has spread rapidly around the world, and the number of cases has increased exponentially.1 Initial reports suggested that patients with cancer have an estimated twofold increased risk of contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared with the general population.2 More importantly, it is expected that COVID-19 will be particularly life threatening in patients with hematological malignancies because of their immune dysfunction. Recent studies have reported an overall COVID-19-related mortality of 29% to 42%3-8 in patients with hematological disease, depending on the type of malignancy, in contrast to the 2% to 7% observed in the general population. Regrettably, there remains a lack of studies about COVID-19 in patients receiving cellular therapies, including chimeric antigen receptor (CAR) T cells.9,10 CAR T cells are genetically modified autologous T cells, which have shown great promise in the treatment of advanced malignant hematological disorders, including non-Hodgkin lymphoma, acute lymphoblastic leukemia, and multiple myeloma.11 CAR T-cell recipients have significant B-cell aplasia requiring immunoglobulin G replacement therapy and may also develop delayed cytopenias, leaving them unable to mount any humoral response to viral infections.12 Shah et al10 demonstrated that the seroconversion rate in a small cohort of patients treated with hemopoietic stem cell transplantation (HSCT) and CAR T-cell therapy did not exceed 66%. According to these observations, the outcomes of COVID-19 in patients treated with CAR T cells remain unclear. The aim of this study was to describe the clinical outcomes of patients developing COVID-19 after treatment with CAR T cells.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Blood Advances
ISSN
2473-9529
e-ISSN
2473-9537
Volume of the periodical
6
Issue of the periodical within the volume
7
Country of publishing house
US - UNITED STATES
Number of pages
7
Pages from-to
2427-2433
UT code for WoS article
001044786600001
EID of the result in the Scopus database
2-s2.0-85125930718